This study is being done to answer the following question: Can we lower the chance of your lung cancer growing or spreading by using a drug that targets a biomarker present in your tumor? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your lung cancer. The usual approach is defined as care most people get for their lung cancer.
Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation NSCLC
St. Joseph's Hospital - West Bend
Community Memorial Hospital
OPEN TO ACCRUAL